Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment

Japanese Journal of Clinical Oncology

Volumn 44, Issue 5, 2014, Pages 479-485

  Kato, Renpei ^a   Obara, Wataru ^a   Matsuura, Tomohiko ^a   Kato, Yoichiro ^a   Iwasaki, Kazuhiro ^a   Fujioka, Tomoaki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse event; Everolimus; Renal cell carcinoma; Survival outcome; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; EVEROLIMUS; GLUCOSE; HEMOGLOBIN; PAZOPANIB; PHOSPHATE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRIACYLGLYCEROL; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAPAMYCIN; VASCULOTROPIN RECEPTOR;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INTERSTITIAL PNEUMONIA; JAPANESE (PEOPLE); KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NAIL DISEASE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; VOMITING; ADVERSE EVENT; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; JAPAN; KIDNEY TUMOR; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; SURVIVAL; SURVIVAL OUTCOME; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR;

ADVERSE EVENT; EVEROLIMUS; RENAL CELL CARCINOMA; SURVIVAL OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84902258857     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu018     Document Type: Article

References (19)

1. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:905-9.
2. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
3. Lynch M, Fitzgerald C, Johnston KA, et al. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol Chem 2004;279:3327-39.
4. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
5. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 2010;116:4256-65.
6. European Association of Urology (EAU) online guideline on renal cell carcinoma. 2010. http://www.uroweb.org/gls/pdf/09_Renal_Cell_ Carcinoma%202010.pdf.
7. NCCN clinical practice guidelines in oncology (NCCN guidelines) kidney cancer, version 2. 2011.
8. Tsukamoto T, Shinohara N, Tsuchiya N, et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2010;41:17-24.
9. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
10. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008;283:34495-9.
11. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-71.
12. Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010;116:5400-6.
13. Robert F, Mills JR, Agenor A, et al. Targeting protein synthesis in a Myc/ mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res 2012;72:747-56.
14. Hudes GR, Berkenblit A, Feingold J, et al. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009;36 (Suppl 3):S26-36.
15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
16. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002;13:2276-88.
17. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004;53:2748-56.
18. Pal SK, Kortylewski M, Yu H, et al. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther 2010;9:3115-25.
19. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20: 2493-502.